DDDD.L Share News (DDDD)

DDDD.L Information

There is currently no data for DDDD

4D pharma progresses with IBS and Crohn's treatments

Tue, 02nd Sep 2014 10:21

4D pharma has announced that its treatments for Irritable Bowel Syndrome (IBS) and Paediatric Crohn's Disease (PCD) are expected to enter clinical studies in the second quarter of 2015. The studies, which will be focused on evaluating safety and tolerability of the products as well as some clinical effects. Blautix, the drug for IBS, and Thetanix, the drug for PCD, both use live bacteria rather than chemical entities or antibodies. Alex Stevenson, 4D's chief scientific officer, said: "The Blautix and Thetanix trials will represent important milestones for the company and a new class of therapeutic, designed to treat the underlying causes of diseases rather than just the symptoms. "In addition, 4D continues to generate a strong pipeline of live biotherapeutics for other important diseases, using its proprietary MicroRx platform."Shares in 4D were up 3.3% to 286.68p by 10:20 on Tuesday.NR

More News

8 Apr 2016 08:25

4D Pharma Buys Assets From Partner In Deal Worth Up To EUR6 Million (ALLISS)

31 Mar 2016 08:47

4d Pharma Annual Loss Widens On Higher Research Spending

26 Feb 2016 15:49

Good news, and some not-so-good news from 4D pharma

(ShareCast News) - 4D pharma brought some good news and some bad news to the market on Friday, over its trials of irritable bowel syndrome (IBS) treatment Blautix, and it paediatric Crohn's disease treatment Thetanix. The AIM-traded pharmaceutical company, with a focus on the development of live bio

26 Feb 2016 09:16

4D Pharma Quality Concerns Delay Thetanix Dosing, Recruits For Blautic

10 Feb 2016 15:12

4D Pharma expands research with Tuscana acquisition

(ShareCast News) - 4D Pharma expanded its research capabilities on Wednesday, acquiring university-based startup Tuscana Health Limited. The AIM traded pharmaceutical company, focused on the development of live biotherapeutics, said Tuscana - based at University College Cork - was founded to investi

10 Feb 2016 08:57

4D Pharma Acquires University Start-Up Company Tucana Health (ALLISS)

19 Jan 2016 07:51

4d Pharma Gets Good Early Results From Blautix Trials

8 Dec 2015 07:46

4d Pharma Raises GBP30.0 Million For Business Development (ALLISS)

26 Nov 2015 10:10

4D Pharma Finds Live Biotherapeutic For Breast, Lung Cancer Treatment

11 Nov 2015 11:15

4D Pharma Gets Approval For Phase 1 Study Of Crohn's Disease Drug

29 Sep 2015 12:08

4D Pharma Progresses Pipeline As It Swings To Loss In First Half

21 Aug 2015 06:49

4D Pharma Commences Dosing In Irritable Bowel Syndrome Clinical Trial

11 Aug 2015 14:15

FTSE 250 movers: Miners drag index down, Synthomer spikes higher

(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews. By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta

7 Aug 2015 06:31

4D Pharma Agrees EUR4.8 Million Collaboration With APC Microbiome

16 Jun 2015 08:33

4D Pharma posts "exciting" development results from MicroRx

Pharmaceutical company 4D Pharma said it had made significant progress in its research efforts using its proprietary platform MicroRx. The Manchester-based outfit was able to identify candidates for the treatment of severe asthma, allergic asthma and rheumatoid arthritis. The group also identified

Latest Share Chat

DDDD.L Share News (DDDD)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

4D pharma progresses with IBS and Crohn's treatments

Login to your account

Quickpicks are a member only feature

Login to your account